|
|
| (3 intermediate revisions by the same user not shown) |
| Line 1: |
Line 1: |
| == '''What is Upadacitinib?''' == | | {{Short description|An article about the medication Upadacitinib}} |
| | {{Drugbox |
| | | verifiedfields = changed |
| | | verifiedrevid = 123456789 |
| | | image = Upadacitinib.svg |
| | | image_size = 200px |
| | | image_alt = Chemical structure of Upadacitinib |
| | }} |
|
| |
|
| * Upadacitinib ('''RINVOQ''') is a '''[[Janus kinase]] (JAK) inhibitor''' used to treat adults with moderate to severe [[rheumatoid arthritis]].
| | '''Upadacitinib''' is a medication used in the treatment of several inflammatory conditions. It is classified as a [[Janus kinase inhibitor]], which works by interfering with the signaling pathways that lead to inflammation. |
|
| |
|
| <youtube>
| | ==Mechanism of Action== |
| title='''{{PAGENAME}}'''
| | Upadacitinib functions by selectively inhibiting the activity of [[Janus kinase]] (JAK) enzymes. These enzymes are crucial in the signaling pathways of various cytokines and growth factors that are involved in hematopoiesis and immune function. By inhibiting JAKs, upadacitinib reduces the inflammatory response that is characteristic of autoimmune diseases. |
| movie_url=http://www.youtube.com/v/v=AzmT5t-01dk
| |
| embed_source_url=http://www.youtube.com/v/v=AzmT5t-01dk
| |
| &rel=1
| |
| wrap = yes
| |
| width=750
| |
| height=600
| |
| </youtube>
| |
|
| |
|
| == '''What are the uses of this medicine?''' == | | ==Medical Uses== |
| | Upadacitinib is primarily used in the treatment of: |
| | * [[Rheumatoid arthritis]] |
| | * [[Psoriatic arthritis]] |
| | * [[Atopic dermatitis]] |
| | * [[Ulcerative colitis]] |
|
| |
|
| * RINVOQ is used to treat adults with moderate to severe [[rheumatoid arthritis]] in whom [[methotrexate]] did not work well or could not be tolerated.
| | ===Rheumatoid Arthritis=== |
| | In patients with moderate to severe [[rheumatoid arthritis]], upadacitinib is used to reduce symptoms and improve physical function. It is often prescribed when patients have had an inadequate response to one or more [[disease-modifying antirheumatic drugs]] (DMARDs). |
|
| |
|
| == '''How does this medicine work?''' == | | ===Psoriatic Arthritis=== |
| | For individuals with active [[psoriatic arthritis]], upadacitinib helps in reducing joint pain and swelling, as well as improving skin symptoms associated with the condition. |
|
| |
|
| * Upadacitinib is a '''[[Janus kinase]] (JAK) inhibitor'''.
| | ===Atopic Dermatitis=== |
| * JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function.
| | Upadacitinib is also indicated for the treatment of moderate to severe [[atopic dermatitis]] in adults and adolescents who are candidates for systemic therapy. |
| * Within the signaling pathway, JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs) which modulate intracellular activity including gene expression.
| |
| * '''Upadacitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs'''.
| |
| * In human leukocyte cellular assays, '''upadacitinib inhibited cytokine-induced STAT phosphorylation mediated by JAK1 and JAK1/JAK3 more potently than JAK2/JAK2 mediated STAT phosphorylation'''.
| |
| * However, the relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known.
| |
|
| |
|
| == '''Who Should Not Use this medicine ?''' == | | ===Ulcerative Colitis=== |
| | In the context of [[ulcerative colitis]], upadacitinib is used to induce and maintain clinical remission in patients with moderate to severe disease. |
|
| |
|
| * This medicine have no usage limitations. | | ==Side Effects== |
| | Common side effects of upadacitinib include: |
| | * [[Upper respiratory tract infections]] |
| | * [[Nausea]] |
| | * [[Headache]] |
| | * [[Hypertension]] |
|
| |
|
| == '''What drug interactions can this medicine cause?''' ==
| | Serious side effects may include: |
| | * Increased risk of serious infections |
| | * [[Thrombosis]] |
| | * [[Liver enzyme elevations]] |
|
| |
|
| * RINVOQ should be used with caution in patients receiving chronic treatment with strong CYP3A4 inhibitors (e.g., [[ketoconazole]]).
| | ==Administration== |
| * Coadministration of RINVOQ with strong CYP3A4 inducers (e.g., [[rifampin]]) is not recommended.
| | Upadacitinib is administered orally, typically once daily. The dosage may vary based on the specific condition being treated and the patient's response to the medication. |
|
| |
|
| == '''Is this medicine FDA approved?''' == | | ==Related pages== |
| | * [[Janus kinase inhibitor]] |
| | * [[Rheumatoid arthritis]] |
| | * [[Psoriatic arthritis]] |
| | * [[Atopic dermatitis]] |
| | * [[Ulcerative colitis]] |
|
| |
|
| * It was approved for use in the United States in 2019.
| | [[Category:Janus kinase inhibitors]] |
| | | [[Category:Immunosuppressants]] |
| == '''How should this medicine be used?''' ==
| | [[Category:Drugs used in rheumatology]] |
| | | <gallery> |
| '''Recommended Dosage '''
| | File:Upadacitinib.svg|Upadacitinib |
| * The recommended oral dose of RINVOQ is 15 mg once daily with or without food.
| | </gallery> |
| * RINVOQ may be used as monotherapy or in combination with [[methotrexate]] or other nonbiologic DMARDs.
| |
| * Avoid initiation or interrupt RINVOQ if absolute lymphocyte count is less than 500 cells/mm3, absolute neutrophil count is less than 1000 cells/mm3, or hemoglobin level is less than 8 g/dL.
| |
| | |
| '''Administration'''
| |
| * Take RINVOQ exactly as your healthcare provider tells you to use it.
| |
| * Take RINVOQ 1 time a day with or without food.
| |
| * Swallow RINVOQ whole with water at about the same time each day. Do not split or break, crush, or chew the tablets.
| |
| | |
| == '''What are the dosage forms and brand names of this medicine?''' ==
| |
| | |
| This medicine is available in fallowing doasage form:
| |
| * '''As Extended-release tablets:''' 15 mg
| |
| | |
| This medicine is available in fallowing brand namesː
| |
| *'''RINVOQ'''
| |
| | |
| =='''What side effects can this medication cause?'''==
| |
| | |
| The most common side effects of this medicine include:
| |
| * upper respiratory tract infections
| |
| * nausea
| |
| * cough
| |
| * [[pyrexia]]
| |
| | |
| RINVOQ may cause serious side effects, including:
| |
| * Serious Infections
| |
| * Cancer
| |
| * Blood Clots ([[thrombosis]])
| |
| * Tears (perforation) in the stomach or intestines
| |
| * Changes in certain laboratory test results
| |
| | |
| ==''' What special precautions should I follow?''' ==
| |
| | |
| * Avoid use of RINVOQ in patients with active, serious infection, including localized infections.
| |
| * Consider the risks and benefits of RINVOQ treatment prior to initiating therapy in patients with a known malignancy.
| |
| * Consider the risks and benefits prior to treating patients who may be at increased risk of [[thrombosis]]. Promptly evaluate patients with symptoms of thrombosis and treat appropriately.
| |
| * Events of gastrointestinal perforation have been reported in clinical studies with RINVOQ. Use with caution in patients who may be at increased risk.
| |
| * Laboratory monitoring is recommended due to potential changes in lymphocytes, neutrophils, hemoglobin, liver enzymes and lipids.
| |
| * RINVOQ may cause fetal harm based on animal studies. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.
| |
| * Avoid use of RINVOQ with live vaccines.
| |
| | |
| == '''What to do in case of emergency/overdose?''' ==
| |
| | |
| * In case of an overdose, it is recommended that the patient be monitored for signs and symptoms of adverse reactions. Patients who develop adverse reactions should receive appropriate treatment.
| |
| | |
| == '''Can this medicine be used in pregnancy?''' ==
| |
| | |
| * The limited human data on use of RINVOQ in pregnant women are not sufficient to evaluate a drug-associated risk for major birth defects or miscarriage.
| |
| | |
| =='''Can this medicine be used in children?'''==
| |
| | |
| * The safety and efficacy of RINVOQ in children and adolescents aged 0 to less than 18 years have not yet been established. No data are available.
| |
| | |
| == '''What are the active and inactive ingredients in this medicine?''' ==
| |
| | |
| * '''Active ingredient:''' upadacitinib
| |
| * '''Inactive ingredients:''' microcrystalline cellulose, hypromellose, mannitol, tartaric acid, colloidal silicon dioxide, magnesium stearate, polyvinyl alcohol, polyethylene glycol, talc, titanium dioxide, ferrosoferric oxide, and iron oxide red.
| |
| | |
| == '''Who manufactures and distributes this medicine?''' ==
| |
| | |
| * '''Manufactured by: '''AbbVie Ireland NL B.V., Sligo, Ireland
| |
| * '''Marketed by:''' AbbVie Inc., North Chicago, IL 60064
| |
| * RINVOQ is a trademark of [[AbbVie Biotechnology Ltd]].
| |
| | |
| == '''What should I know about storage and disposal of this medication?''' ==
| |
| * Store RINVOQ in original container at 36°F to 77°F (2°C to 25°C) to protect it from moisture.
| |
| * Keep RINVOQ and all medicines out of the reach of children.
| |
| | |
| {{Extracellular chemotherapeutic agents}}
| |
| {{Cytokine receptor modulators}}
| |
| {{Portal bar | Medicine}}
| |
| | |
| [[Category:AbbVie brands]]
| |
| [[Category:Anti-inflammatory agents]]
| |
| [[Category:Non-receptor tyrosine kinase inhibitors]] | |
| [[Category:Organofluorides]] | |
| [[Category:Pyrrolidines]] | |
| [[Category:Trifluoromethyl compounds]]
| |
| [[Category:Ureas]]
| |
| {{coststubd}}
| |
An article about the medication Upadacitinib
Upadacitinib is a medication used in the treatment of several inflammatory conditions. It is classified as a Janus kinase inhibitor, which works by interfering with the signaling pathways that lead to inflammation.
Mechanism of Action[edit]
Upadacitinib functions by selectively inhibiting the activity of Janus kinase (JAK) enzymes. These enzymes are crucial in the signaling pathways of various cytokines and growth factors that are involved in hematopoiesis and immune function. By inhibiting JAKs, upadacitinib reduces the inflammatory response that is characteristic of autoimmune diseases.
Medical Uses[edit]
Upadacitinib is primarily used in the treatment of:
Rheumatoid Arthritis[edit]
In patients with moderate to severe rheumatoid arthritis, upadacitinib is used to reduce symptoms and improve physical function. It is often prescribed when patients have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs).
Psoriatic Arthritis[edit]
For individuals with active psoriatic arthritis, upadacitinib helps in reducing joint pain and swelling, as well as improving skin symptoms associated with the condition.
Atopic Dermatitis[edit]
Upadacitinib is also indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents who are candidates for systemic therapy.
Ulcerative Colitis[edit]
In the context of ulcerative colitis, upadacitinib is used to induce and maintain clinical remission in patients with moderate to severe disease.
Side Effects[edit]
Common side effects of upadacitinib include:
Serious side effects may include:
Administration[edit]
Upadacitinib is administered orally, typically once daily. The dosage may vary based on the specific condition being treated and the patient's response to the medication.
Related pages[edit]
Upadacitinib